Loading…
Loading…
EW · NYSE · Healthcare
“At 44.6 times earnings, Edwards Lifesciences demands extraordinary growth execution to justify its premium valuation against conservative intrinsic value calculations.”
— In the voice of Graham
Project future earnings using analyst estimates and historical growth rates. Model 5-year earnings trajectories.
Market Cap
$47.91B
P/E Ratio
44.63
Forward P/E
—
EPS
$1.84
PEG Ratio
-0.59
Book Value
$17.68
Dividend Yield
—
Profit Margin
17.69%
ROE
10.38%
Use the interactive growth projection with pre-loaded data for Edwards Lifesciences Corp. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for EW: